Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors [2] - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London, the San Francisco Bay Area, and New Jersey [3] Product Development - ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [2] - The company has multiple ADCs in ongoing clinical and preclinical development [2] Upcoming Events - Ameet Mallik, CEO of ADC Therapeutics, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on March 12, 2024 [1] - A live webcast of the presentation will be available on the company's Investors section of the website [1]

The market expects ADC Therapeutics SA (ADCT) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, ...

Core Insights - The article emphasizes the potential for significant wealth creation through investing in undervalued biotech stocks, highlighting examples of companies that have experienced substantial price increases over time [1]. Group 1: Company Highlights - ACADIA Pharmaceuticals (ACAD) saw its stock price rise from $0.70 to a high of $45.10, representing a gain of approximately 6,300% [1]. - CRISPR Therapeutics (CRSP) experienced a surge from around $40 to nearly $77.50 [1]. - Corbus Pharmaceuticals (CRBP) increased from about $5 to nearly $40 following positive Phase 1 trial results for a cancer drug [1]. Group 2: Viking Therapeutics (VKTX) - Viking Therapeutics (VKTX) has risen from approximately $8.50 to a recent high of $24.63 but is still considered undervalued despite positive trial data for its obesity treatment [2]. - The potential for VKTX is underscored by the success of Eli Lilly's obesity drug, Zepbound, which generated $175.8 million in sales in less than a month, exceeding Wall Street's expectations of $75 million [2]. - VKTX's promising Phase 1 study results for VK2735 indicate potential for weight loss, and there is speculation it could be a takeover target [2]. Group 3: ADC Therapeutics (ADCT) - ADC Therapeutics (ADCT) specializes in antibody-drug conjugates (ADCs) and has seen its stock price rise from about $0.50 to $4, yet remains undervalued [3][4]. - ADCs are gaining traction in the biotech sector, as evidenced by Pfizer's $43 billion acquisition of Seagen and interest in acquiring more ADC companies [5]. - ADCT's recent trial results for a combination treatment for relapsed follicular lymphoma showed a 96% overall response rate and an 85% complete response rate, indicating strong potential for future growth [5]. Group 4: Intellia Therapeutics (NTLA) - Intellia Therapeutics (NTLA), a gene editing company, is currently undervalued and has significant upside potential, especially after the success of its competitor, CRISPR Therapeutics [6]. - Cathie Wood's Ark Invest recently acquired 131,000 shares of NTLA, representing 11% of the outstanding shares [6]. - Positive interim Phase 1 data for NTLA-2002, published in The New England Journal of Medicine, suggests that a single dose may eliminate angioedema attacks in patients [6][7]. - NTLA is set to initiate a global pivotal study for NTLA-2002 in the second half of the year, providing solid catalysts for future growth [7].

Economic Overview - The U.S. economy added 353,000 jobs in January, significantly exceeding the Dow Jones estimate of 185,000 [1] - Average hourly earnings increased by 0.6% month-over-month and 4.5% year-over-year, surpassing economists' expectations [1] Market Sentiment - Traders are less enthusiastic about strong economic data as it reduces the urgency for the Federal Reserve to cut interest rates [1][2] - There is a perception that some traders prefer a weak economy to facilitate rate cuts rather than supporting long-term earnings growth [2] Biotech Sector Performance - The biotech sector is experiencing significant profit-taking, with notable gains reported by Luke Lango's trading service, High Velocity Stocks [2][3] - Recent profits include 30% gains from Autolus Therapeutics, 40% from Amneal Pharmaceuticals, and 100% from Ardelyx [3] Future Outlook for Biotech - A "2024 Biotech Boom" is anticipated, driven by lower interest rates and improving risk sentiment [4] - The prospect of lower interest rates is expected to positively impact biotech R&D funding, which is often debt-financed [4] Impact of Artificial Intelligence - AI is poised to revolutionize drug discovery economics by increasing success rates and reducing costs and timelines for clinical trials [6] - Hypothetical scenarios suggest that AI could lower average drug development costs from $2.6 billion to less than $1.5 billion [6][7] Stage Analysis Framework - The stage analysis framework focuses on stock price action and momentum, identifying stocks on the verge of breakout [8][9] - The biotech sector is currently in Stage-1 consolidation, with potential for a Stage-2 breakout, which could lead to significant gains [10][11] Investment Strategies - Investors can choose between a buy-and-hold strategy for long-term exposure to biotech or a more active trading approach based on price momentum [12][13] - A conservative approach suggests waiting for the SPDR S&P Biotech ETF (XBI) to break above its Stage-1 resistance level of approximately $95 before initiating trades [13]

ADC Therapeutics (ADCT) is a commercial-stage biotech company focused on developing novel antibody-drug conjugates (ADC) to treat patients with hematologic malignancies and solid tumors.Currently, ADC Therapeutics has only one marketed drug in its portfolio, Zynlonta, which the FDA approves to treat relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in the third or later-line setting.Management is also evaluating Zynlonta in combination with other agents and earlier lines of therapy. Apart f ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ADC Therapeutics SA (ADCT) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.ADC Therapeutics SA is a member of our Medical group, which includes 1077 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 dif ...

Core Insights - The cancer drug market, particularly antibody-drug conjugates (ADCs), is experiencing significant growth and interest from various companies, as highlighted during the JPMorgan Healthcare Conference in San Francisco [1][2] - Johnson & Johnson's recent $2 billion acquisition of Ambrx Biopharma is indicative of the strategic moves companies are making to enhance their ADC pipelines, with other major players like Pfizer and Merck also engaging in ADC-related deals [2] - Analysts predict continued advancements and deal-making in the ADC space, driven by increased confidence in the technology and the potential for substantial profits, with ADCs projected to represent $31 billion of the $375 billion global cancer market by 2028 [3] Industry Trends - The enthusiasm for ADCs is fueled by their ability to specifically target cancer cells while minimizing damage to healthy cells, contrasting with traditional chemotherapy [1] - The ADC market was valued at approximately $9.7 billion in 2023, indicating a robust foundation for future growth [3] - The fear of missing out (FOMO) among companies not yet involved in the ADC market is likely to drive further entries and investments into this sector [2][3]

ZYNLONTA®1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023 LOTIS-7: Study of ZYNLONTA in combination with bispecifics cleared first dosing cohort​ with no DLT and with early signs of efficacy ADCT-601 (targeting AXL): Reached MTD and currently in dose optimization; Early signs of antitumor activity in both monotherapy and in combination Multiple data catalysts expected in 2024 and with a cash runway now expected into 4Q 2025 LAUSANNE, Switzerland, ...

Love Employee Overview ADCs - antigen-drug conjugants - are among the hottest developments in cancer treatments. In combination with other drugs, they hold the promise of replacing chemotherapy on a whole host of cancers, because, unlike chemo, which is systemic and comes with severe side effects, ADCs target specific tumors with minimal impacts on healthy tissue. Sometimes called "Smart chemo," and "Cancer guided missiles," ADC's work by delivering a combination of an antibody and a cancer-cell killer to a ...

ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Eugenia Litz - Vice President of Investor Relations and Corporate Communications Ameet Mallik - Chief Executive Officer Kristen Herrington-Smith - Chief Commercial Officer Mohamed Zaki - Chief Medical Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Naureen Quibria - Capital One Securities Brian Cheng - JPMorgan Operator Welcome to the ADC Therapeutics Third Quarter 20 ...